Company Research Report: Amneal Pharmaceuticals, Inc.
Company Overview
- Name: Amneal Pharmaceuticals, Inc.
- Mission: Amneal believes in making essential medicines more accessible and improving healthcare outcomes globally; the slogan is "We make healthy possible."
- Founded: 2002
- Founders: Chirag Patel and Chintu Patel
- Key People:
- Paul Meister, Chairman
- Chirag Patel, Co-Chief Executive Officer and President
- Chintu Patel, Co-Chief Executive Officer
- Headquarters: Bridgewater, NJ, USA
- Number of Employees: 7,800+
- Revenue: No information is available
- Known For: Amneal is recognized for its broad pharmaceutical portfolio, including over 280 generic and specialty products, and a strong presence in the generics market in the U.S.
Products
Generic Products
- Description: Amneal's generics portfolio includes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals. It spans a broad range of therapeutic categories with more than 270 products.
- Key Features: Emphasizes difficult-to-manufacture products and high-barrier-to-entry medications like oncologics and anti-infectives.
Specialty Products
- Description: The specialty product line focuses on proprietary medicines within core therapeutic categories, including neurology (e.g., Parkinson's Disease, Migraine) and endocrinology (e.g., Hypothyroidism).
- Notable Products:
- CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules: Approved for treating Parkinson’s disease.
- Rytary (Carbidopa & Levodopa) Extended Release Capsules
- Ongentys (opicapone)
- Unithroid (Levothyroxine)
- Zomig (zolmitriptan) Nasal Spray
Biosciences Products
- Description: Focus on biosimilars and specialty injectables for therapeutic areas like oncology and movement disorders.
- Key Features: Offers increased choice and affordability, primarily marketed through U.S.-based account managers.
Recent Developments
- New Products Launched:
- Pyridostigmine Bromide Extended-Release Tablets: Approved by FDA, used for pretreatment against soman nerve agent for the U.S. Armed Services.
- BORUZU™: Ready-to-use version of Bortezomib.
- FOCINVEZ™: First ready-to-use version of Fosaprepitant.
- New Features Added: No information is available
- Partnerships:
- Collaboration with Metsera to develop and supply next-generation medicines for obesity and metabolic diseases.
- Partnership with Shilpa for the FDA-approved BORUZU™ product.
Conclusion
This report highlights Amneal Pharmaceuticals' strong portfolio in generic and specialty pharmaceuticals, its expansion into biosimilars, and growing international presence. Significant investments in research and development continue to drive product innovation and accessibility in the pharmaceutical landscape.
